New eye scan could spot drug damage before vision fades
NCT ID NCT07409740
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will use a non-invasive eye scan called OCTA to look for tiny blood vessel changes in the retina of 90 adults who have taken hydroxychloroquine for at least a year. Hydroxychloroquine, used for autoimmune diseases, can sometimes harm the retina with long-term use. The goal is to see if OCTA can detect early signs of damage, which could help doctors monitor patients more closely and prevent vision loss.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better screening methods to catch hydroxychloroquine-related eye damage early, helping prevent vision loss.
- What could go wrong
- This is an observational study, not a treatment trial. It may not change current monitoring practices, and results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study includes adults receiving hydroxychloroquine therapy for autoimmune diseases and a control group of healthy volunteers. The aim is to evaluate retinal microvascular changes using OCTA imaging.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults (≥18 years old) with documented HCQ therapy for ≥1 year. * Stable systemic disease under medical supervision. Exclusion Criteria: * -patients with media opacity. * Any pre-existing retinal or optic nerve disease (e.g., diabetic retinopathy, AMD, myopic degeneration). * History of intraocular surgery or trauma. * Uncontrolled systemic vascular diseases (e.g., hypertension)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hydroxychloroquine retinopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.